Skip to content

Author

M. S. Abizaid

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Changing Patterns of Cutaneous Melanoma Mortality in Brazil: A Nationwide Time-Series Analysis (2000-2024)

Background: Cutaneous melanoma accounts for most deaths from skin cancer, and mortality is consistently higher in men than in women. National trends in Brazil have not been characterized using population estimates rebased to the 2022 Census. Materials and methods: We conducted a nationwide ecological time-series study of deaths from cutaneous melanoma (ICD-10 C43) recorded in Brazil’s Mortality Information System from 2000 to 2024. Population denominators were obtained from the 2024 revision of the Brazilian Institute of Geography and Statistics projections, rebased to the 2022 Census. Rates were directly age-standardized to the 2022 Brazilian population; 95% confidence intervals (CIs) were estimated using the Fay-Feuer gamma method, a standard approach for deriving exact confidence limits for standardized rates from count data. National and subgroup trends were assessed using segmented log-linear regression, which identifies the calendar years in which a trend changes direction. Differences by sex, region, and age group were examined using age-adjusted negative binomial models with population offsets, which compare death rates between groups of different population sizes. The sex interaction was prespecified as a secondary, exploratory comparison and was not adjusted for multiple testing. The COVID-19 period was assessed using an interrupted time-series model with 2020 specified a priori. Results: Between 2000 and 2024, 38,346 deaths were attributed to cutaneous melanoma. Annual deaths increased from 1,027 to 2,031, whereas the age-standardized rate was essentially unchanged, from 0.91 to 0.92 per 100,000 population. Mortality increased by 0.83% per year (95% CI 0.52 to 1.14) until 2016 and declined by 1.12% per year (−1.69 to −0.54) thereafter. The full-period average annual percentage change (AAPC) was 0.17% (−0.01 to 0.36; p = 0.065). Men had higher rates throughout. Sex-specific segmented models showed an increase followed by a decline in men and an overall stable trend in women. An exploratory, non-multiplicity-adjusted interaction offered limited and inconsistent evidence of a more favorable trajectory in women than in men (p = 0.037). Mortality declined in all groups younger than 60 years and increased overall among adults aged 60 years or older, although the rise leveled off after 2015. The Southeast declined, the South was stable overall, and the North and Northeast increased from very low initial rates. The pandemic was associated with a one-time 6.60% downward shift in mortality in 2020, without a change in slope. Using population estimates not rebased to the 2022 Census changed the national AAPC from 0.17% (−0.01 to 0.36) to −0.39% (−0.60 to −0.18). Conclusions: The increasing number of melanoma deaths in Brazil was driven largely by population growth and aging rather than by a sustained increase in age-standardized mortality. A national decline began around 2016, but trends remained heterogeneous by age and region. The material change in the national AAPC after revision of the population denominators demonstrates that denominator vintage is not merely a technical consideration in long-term mortality studies but can materially affect epidemiological conclusions.

M. Ribeiro, M. S. Abizaid, Maria Eduarda K. Garcia et al. · 0 citations
Open access Jul 2026

Tendências Temporais e Desfechos Intra-Hospitalares do Implante de Bioprótese Aórtica Transcateter em Valvas Aórticas Bicúspides no Brasil: Uma Análise Pareada por Escore de Propensão

RESUMO Fundamento: A valva aórtica bicúspide (VAB) é um fator de risco importante para estenose aórtica. No entanto, os desfechos do implante de bioprótese aórtica transcateter (TAVI) permanecem pouco claros, já que a maioria dos ensaios clínicos randomizados excluiu esses pacientes. Além disso, grande parte das evidências publicadas sobre o TAVI em VAB advém de países de alta renda, o que pode não refletir a realidade de países em desenvolvimento. Objetivos: Avaliar tendências temporais, características do procedimento e desfechos intra-hospitalares entre pacientes com VAB e valva aórtica tricúspide (VAT). Métodos: Estudo observacional retrospectivo baseado em um registro multicêntrico brasileiro de pacientes submetidos ao TAVI entre janeiro de 2009 e dezembro de 2021. Realizamos pareamento por escore de propensão para ajustar as comparações. Um valor de p<0,05 foi considerado estatisticamente significativo para todas as análises. Resultados: Entre 2426 pacientes de 25 centros, 111 tinham VAB. Os procedimentos de TAVI aumentaram ao longo do tempo em ambos os grupos. Após o pareamento na proporção de um para três, foram incluídos 90 pacientes com VAB e 243 com VAT. Não foram observadas diferenças significativas nas taxas de complicações vasculares maiores (4% vs. 5%; p=0,99), sangramento maior ou com risco de vida (10% vs. 6%; p=0,34), acidente vascular cerebral (AVC) (2% vs. 0,4%; p=0,37) ou mortalidade intra-hospitalar (7% vs. 3%; p=0,21). Ao longo do tempo, houve redução significativa na mortalidade intra-hospitalar (p<0,01) e nas principais complicações do procedimento (p<0,01 para eventos vasculares, sangramento e AVC), independentemente do tipo de valva. Conclusão: Durante o período do estudo, os procedimentos anuais de TAVI aumentaram tanto em pacientes com VAB quanto com VAT, embora a prevalência de VAB tenha permanecido relativamente baixa. Não houve diferenças significativas nos desfechos do procedimento ou clínicos entre os grupos pareados por escore de propensão, com redução das complicações do procedimento e da mortalidade para ambos os tipos de valva ao longo do tempo.

Pedro Calomeni, Fernando L. M. Bernardi, F. Brito et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.